Enthusiasm Builds For Biogen’s BAN2401 In Alzheimer's, But SMA Gene Therapy Hits A Snag
The company told its Q2 call it plans to talk to regulators about a filing strategy for the amyloid-targeting antibody based on Phase II data. Spinraza had a strong quarter, but Biogen’s SMA gene therapy is on clinical hold.
You may also be interested in...
Biogen's Busy Pipeline: Continued Confusion On BAN2401, But Other Irons In The Fire
Company highlighted recent pipeline advances in a variety of neuroscience indications during its third-quarter earnings report.
Alzheimer's Early Approval? Skepticism Over Biogen/Eisai's BAN2401 Data Clouds Chances
18-month Phase II data on amyloid-targeting antibody BAN2401, presented at AAIC, raised more questions than they answered – and seemed to take the wind out of the sails for an early regulatory filing.
Biogen, Eisai Report BAN2401 Seemingly Positive In Alzheimer's; Others Skeptical
Further new data for the Biogen and Eisai drug BAN2401 appear to show it significantly reduces amyloid plaque and cognitive declines in Alzheimer's patients in a dose-dependent manner, but a lot of questions – and skepticism about the data – remain.